Siemens Healthineers posted a 3.9% decline in reported revenue in its second quarter of fiscal year 2026, citing a sharp drop in its Diagnostics unit.
For the period (end-March 31), the company’s total revenue was €5.681 billion ($6.42 billion), down from €5.909 billion ($6.68 billion) in the same period last year. Net income declined 4.5% year-over-year to €512 million ($578 million), down from €537 million ($607 million) in the prior-year quarter. Adjusted basic earnings per share came in at €0.53 ($0.60), nearly on par with €0.56 ($0.63) in the prior-year quarter. Tariffs and negative currency effects weighed on margins, the company said.
On a segment basis:
Imaging revenue rose 6.1% on a comparable basis to €2.973 billion ($3.36 billion), with Magnetic Resonance and Molecular Imaging each achieving very strong growth, Siemens said. Adjusted EBIT margin was 22.4%.
Precision Therapy grew 4.7% on a comparable basis to €1.702 billion ($1.92 billion), driven by Varian, which posted 7.5% comparable growth. Adjusted EBIT margin was 13.3%.
Diagnostics revenue declined 6.5% on a comparable basis to €985 million ($1.11 billion), with China revenue falling sharply due to what the company described as a structural change in that market. Adjusted EBIT margin fell to 0.9% from 6.3% in the prior-year quarter.
The company updated its fiscal year 2026 outlook, narrowing its comparable revenue growth expectation to between 4.5% and 5.0% (previously 5% to 6%) and its adjusted basic earnings per share guidance to between €2.20 ($2.49) and €2.30 ($2.60) (previously €2.20 ($2.49) and €2.40 ($2.71)).
